[go: up one dir, main page]

WO2013036031A3 - microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물 - Google Patents

microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2013036031A3
WO2013036031A3 PCT/KR2012/007112 KR2012007112W WO2013036031A3 WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3 KR 2012007112 W KR2012007112 W KR 2012007112W WO 2013036031 A3 WO2013036031 A3 WO 2013036031A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
neurological disorders
pharmaceutical composition
treating neurological
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/007112
Other languages
English (en)
French (fr)
Other versions
WO2013036031A2 (ko
Inventor
강수경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Publication of WO2013036031A2 publication Critical patent/WO2013036031A2/ko
Publication of WO2013036031A3 publication Critical patent/WO2013036031A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 miRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물에 관한것으로서, 더욱 상세하게는, miR486 억제제를 이용한 miR486의 발현 간섭이 NeuroD6의 억제를 회복함으로써 척수 손상(spinal cord injury, SCI) 개선을 유도하는 것을 확인하였으므로, 상기 miR486 억제제는 신경계 질환 예방 및 치료용 약학적 조성물의 유효성분으로 사용이 가능하며, miR486가 NeuroD6의 발현을 조절하는 기작을 신경계 질환 예방 및 치료용 후보물질을 스크리닝하는데 사용할 수 있다.
PCT/KR2012/007112 2011-09-06 2012-09-05 microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물 Ceased WO2013036031A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110090424A KR20130026950A (ko) 2011-09-06 2011-09-06 ｍｉｃｒｏＲＮＡ４８６ 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물
KR10-2011-0090424 2011-09-06

Publications (2)

Publication Number Publication Date
WO2013036031A2 WO2013036031A2 (ko) 2013-03-14
WO2013036031A3 true WO2013036031A3 (ko) 2013-07-11

Family

ID=47832704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007112 Ceased WO2013036031A2 (ko) 2011-09-06 2012-09-05 microRNA486 발현 억제제를 유효성분으로 포함하는 신경계 질환 예방 및 치료용 약학적 조성물

Country Status (2)

Country Link
KR (1) KR20130026950A (ko)
WO (1) WO2013036031A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304041B1 (ko) 2019-12-24 2021-09-24 경북대학교 산학협력단 microRNA 억제제를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (ko) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100049079A (ko) * 2007-07-18 2010-05-11 더 리젠트스 오브 더 유니버시티 오브 콜로라도 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOHAMMAD M. GHAHRAMANI SENO ET AL.: "Gene and miRNA expression profiles in autism spectrum disorders", BRAIN RESEARCH, vol. 1380, 22 March 2011 (2011-03-22), pages 85 - 97, XP028161669 *

Also Published As

Publication number Publication date
KR20130026950A (ko) 2013-03-14
WO2013036031A2 (ko) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2014144100A3 (en) Sgc stimulators
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
IN2014DN09804A (ko)
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
IL195217A0 (en) Protein kinase inhibitors and uses thereof
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2013170072A3 (en) Compounds for the treatment of neurological disorders
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EP3182979A4 (en) Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12829806

Country of ref document: EP

Kind code of ref document: A2